Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones

Agnès-Laurence Chenine,Melanie Merbah,Lindsay Wieczorek,Sebastian Molnar,Brendan Mann,Jenica Lee,Anne-Marie OʼSullivan,Meera Bose,Eric Sanders-Buell,Gustavo H. Kijak,Carolina Herrera,Robert McLinden,Robert J. OʼConnell,Nelson L. Michael,Merlin L. Robb,Jerome H. Kim,Victoria R. Polonis,Sodsai Tovanabutra

Neutralization Sensitivity of a Novel HIV-1 CRF01_AE Panel of Infectious Molecular Clones

2018

Agnès-Laurence Chenine
Melanie Merbah
Lindsay Wieczorek
Sebastian Molnar
Brendan Mann
Jenica Lee
Anne-Marie OʼSullivan
Meera Bose
Eric Sanders-Buell
Gustavo H. Kijak
Carolina Herrera
Robert McLinden
Robert J. OʼConnell
Nelson L. Michael
Merlin L. Robb
Jerome H. Kim
Victoria R. Polonis
Sodsai Tovanabutra

Background:HIV-1 CRF01_AE is dominant in Thailand where RV144 vaccine trial was conducted. To study immune correlates of protection in ongoing trials, CRF01_AE-derived reagents are essential. Here, we present a panel of 14 HIV-1 infectious molecular clones (IMCs) identified from different stages of

Keywords:

Immunology
Neutralization
Virology
Medicine
human immunodeficiency virus
Vaccine trial
immune correlates

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations